Bris­tol-My­ers passed on its $475M deal to op­tion F-star drug; Zymeworks IPO rais­es $59M

→ A lit­tle more than two years ago, Bris­tol-My­ers agreed to ante up $50 mil­lion to get an op­tion on F-star’s ex­per­i­men­tal can­cer drug for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.